for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

North China Pharmaceutical Co., Ltd.

600812.SS

Latest Trade

11.06CNY

Change

-0.39(-3.41%)

Volume

10,879,936

Today's Range

10.92

 - 

11.50

52 Week Range

6.24

 - 

20.24

As of on the Shanghai Stock Exchange ∙ Minimum 15 minute delay

Pricing

Previous Close
11.45
Open
11.47
Volume
10,879,936
3M AVG Volume
726.51
Today's High
11.50
Today's Low
10.92
52 Week High
20.24
52 Week Low
6.24
Shares Out (MIL)
1,630.80
Market Cap (MIL)
18,884.72
Forward P/E
--
Dividend (Yield %)
0.26

Latest Developments

更多

North China Pharmaceutical Gets Regulatory Approval For Asset Acquisition

Jizhong Energy Resources Raises Holdings In North China Pharmaceutical To 25.3%

North China Pharmaceutical Plans Acquisition Via Cash, Share Issue

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About North China Pharmaceutical Co., Ltd.

North China Pharmaceutical Co., Ltd. is a China based company principally engaged in the research and development, production and sales of pharmaceuticals. The Company is mainly engaged in the research and development, production and sales of chemical raw materials, chemical preparations, biological preparations, pharmaceutical intermediates and nutraceuticals. The Company's products are covered in infective drugs, biotech drugs, cardio cerebrovascular drugs, nephropathy and immunomodulatory drugs, cancer therapeutic drugs, vitamins and nutraceuticals. In addition, The Company is also engaged in pharmaceutical logistics business. The Company distributes its products within the domestic market and to overseas markets.

Industry

Biotechnology & Drugs

Contact Info

No. 388, Heping East Road

SHIJIAZHUANG, HEB

050015

China

+86.311.86691718

http://www.ncpc.com

Executive Leadership

Haijing Yang

Chairman of the Board, Finance Director, Chief Accounting Officer, Secretary of the Board

Wenfu Liu

Vice Chairman of the Board, General Manager

Guitong Liu

Deputy General Manager, Director

Renlong Gao

Deputy General Manager

Jie Tong

Deputy General Manager

Key Stats

3.00 mean rating - 1 analysts
Sell
Hold
Buy
Revenue (MM, CNY)

2020(E)

12.7K
EPS (CNY)

2020(E)

0.110
Price To Earnings (TTM)
99.18
Price To Sales (TTM)
1.64
Price To Book (MRQ)
3.35
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
207.10
LT Debt To Equity (MRQ)
60.96
Return on Investment (TTM)
2.09
Return on Equity (TTM)
0.91

Latest News

Latest News

中国股市收涨 决策者承诺采取改革和流动性措施支撑人气

中国股市周四收涨,因决策者安抚投资人,经济将逐渐从新冠危机中复苏,他们同时承诺将采取更多改革和流动性措施支撑资本市场。

中国股市收高 低迷贸易数据激发对出炉更多政策刺激的冀望

中国股市周一收高,因最新国内贸易数据表现低迷,强化对于当局将采取更多政策刺激来提振受疫情所打击经济的希望。

中国股市收高 因指标贷款利率再度下调

沪深300指数<.CSI300>收升0.36%,沪深300金融地产指数收升0.2%,沪深300主要消费指数收升0.38%,沪深300地产指数收跌0.39 %,沪深300医药卫生指数收升0.7 %。

中国股市收盘持平 投资者等待中美贸易协议的进一步进展

沪综指<.SSEC>收盘持平于3,017.07点。该指数本月迄今涨逾5%,因投资者期待中美初步贸易协议的更多细节将会公布。

中国股市收高 中美贸易协议签署在望激励乐观情绪

沪深300指数<.CSI300>涨0.7%至3,978.12点,沪综指<.SSEC>涨0.6%至2,975.49点。

沪综指收跌1% 贸易谈判不确定性扰动市场神经

沪深300指数<.CSI300>收跌1.14%报3,890.66点,沪综指<.SSEC>收跌0.98%报2,977.08点。

中国股市收高创6月底来最大周涨幅 受中美谈判和刺激政策期冀提振

中国股市周五收高,录得6月底以来最大周线涨幅,因中国政府承诺进一步促进经济增长,同时中美贸易紧张情势降温。

中国股市收高 中国可能采取刺激措施且中美确认10月进行贸易谈判

中国股市周四收高,投资者寄望中国将释出银行存款准备金刺激经济,而中美将在10月举行新一轮经贸磋商的消息亦提振人气。

中国股市月线收低 关税威胁挥之不去

中国股市周五涨跌互现,投资者对中美最新贸易谈判迹象的乐观情绪,被华府坚持从9月1日开始对中国输美商品加征关税的决定所抵消。

中国股市收高 工业企业利润数据激发出台进一步刺激的预期

中国股市在连跌两日后周三收高,美股反弹提振人气,同时疲弱的工业企业利润数据激发了政府出台更多刺激的预期。

综述:中国A股收创逾25个月最大单日涨幅 多因素促大盘强劲反弹

中国股市沪综指周一收升近2.5%,创逾25个月最大单日涨幅。中美贸易争端明朗化后,短期利空因素出尽,加之周末利好消息激励,资金面略显宽松,诸多因素结合促使大盘出现一波较大反弹。

沪综指收升2.5%创逾25个月最大单日涨幅 受A股开放利好刺激

中国股市沪综指周一收升2.5%,创逾25个月最大单日涨幅。分析师指出,受A股对外国投资者进一步放开的利好消息激励,今日大盘强劲反弹,个股普涨,金融股和医药股涨幅居前,但量能未见放大。在连涨两日后,短期技术指标显示有超买迹象,大盘短线有消化调整需要。

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up